Nov 14, 2024 | Business, Data Analytics, Diabetes, Disease Area Trends
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....
Nov 14, 2024 | Business, Industry Trends
M&A mania is here. Unprecedented deal values for mergers and acquisitions dominated in 2014. Worldwide M&A was up 47% since 2013 with 95 deals valued greater than $5 billion, as reported by Reuters. Most deals were transacted in the energy,...
Nov 14, 2024 | Business, Chronic Disease, Diabetes, Disease Area Trends
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio...
